Last 7 days
-21.0%
Last 30 days
-19.6%
Last 90 days
-28.2%
Trailing 12 Months
-31.6%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-08-08 | SOOD NITIN | sold | -68,997 | 6.54 | -10,550 | chief commercial officer, mrd |
2023-08-07 | SOOD NITIN | sold | -38,320 | 6.78 | -5,652 | chief commercial officer, mrd |
2023-06-20 | PETERSON TYCHO | acquired | 985,215 | 7.3 | 134,961 | chief financial officer |
2023-06-20 | PETERSON TYCHO | sold | -1,098,580 | 8.14 | -134,961 | chief financial officer |
2023-06-15 | PETERSON TYCHO | acquired | 104,594 | 7.3 | 14,328 | chief financial officer |
2023-06-15 | PETERSON TYCHO | sold | -597,100 | 8.53 | -70,000 | chief financial officer |
2023-06-02 | PETERSON TYCHO | sold | -272,080 | 7.16 | -38,000 | chief financial officer |
2023-04-11 | ADAMS R MARK | sold | -19,918 | 8.63 | -2,308 | chief operating officer |
2023-04-10 | ADAMS R MARK | sold | -6,944 | 8.5 | -817 | chief operating officer |
2023-03-27 | GRIFFIN MICHELLE RENEE | sold | -19,878 | 8.4913 | -2,341 | - |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-09-12 | Farther Finance Advisors, LLC | unchanged | - | -108 | 342 | -% |
2023-09-07 | Triatomic Management LP | added | 58.26 | 136,999 | 813,024 | 0.83% |
2023-08-23 | Rappaport Reiches Capital Management, LLC | unchanged | - | -144,329 | 456,817 | 0.19% |
2023-08-22 | Asset Dedication, LLC | added | 5.44 | -3,000 | 8,000 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | unchanged | - | -43,248 | 136,884 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -64.56 | -333,907 | 123,052 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.63 | -297,174 | 845,393 | -% |
2023-08-18 | Legato Capital Management LLC | added | 39.55 | 38,287 | 671,248 | 0.09% |
2023-08-16 | Nuveen Asset Management, LLC | reduced | -39.11 | -5,817,430 | 5,009,570 | -% |
2023-08-15 | CAPTRUST FINANCIAL ADVISORS | added | 0.57 | -25,245 | 81,828 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 13, 2023 | blackrock inc. | 8.7% | 12,374,197 | SC 13G | |
Feb 09, 2023 | vanguard group inc | 8.25% | 11,794,168 | SC 13G/A | |
Sep 12, 2022 | price t rowe associates inc /md/ | 2.9% | 4,081,518 | SC 13G/A | |
Feb 14, 2022 | viking global investors lp | 21.3% | 29,993,708 | SC 13G/A | |
Feb 14, 2022 | matrix capital management company, lp | 8.20% | 11,572,590 | SC 13G/A | |
Feb 10, 2022 | price t rowe associates inc /md/ | 9.4% | 13,286,713 | SC 13G | |
Feb 10, 2022 | price t rowe associates inc /md/ | 10.0% | 14,240,614 | SC 13G/A | |
Feb 09, 2022 | vanguard group inc | 7.82% | 11,031,288 | SC 13G/A | |
Feb 16, 2021 | matrix capital management company, lp | 9.59% | 13,115,090 | SC 13G/A | |
Feb 16, 2021 | viking global investors lp | 21.9% | 29,993,708 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Sep 01, 2023 | 8-K | Current Report | |
Aug 08, 2023 | 4 | Insider Trading | |
Aug 08, 2023 | 144 | Notice of Insider Sale Intent | |
Aug 02, 2023 | 8-K | Current Report | |
Aug 02, 2023 | 10-Q | Quarterly Report | |
Jul 03, 2023 | 8-K | Current Report | |
Jun 21, 2023 | 4 | Insider Trading | |
Jun 20, 2023 | 4 | Insider Trading | |
Jun 20, 2023 | 144 | Notice of Insider Sale Intent | |
Jun 15, 2023 | 144 | Notice of Insider Sale Intent |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
A | 33.0B | 7.0B | -5.38% | -12.23% | 29.09 | 4.71 | 5.03% | -14.68% |
MTD | 24.7B | 4.0B | -3.30% | -3.12% | 27.83 | 6.25 | 2.30% | 16.37% |
ILMN | 21.9B | 4.5B | -17.36% | -28.94% | -5.22 | 4.9 | -4.92% | -21931.58% |
TECH | 11.2B | 1.1B | -9.93% | -5.35% | 39.16 | 9.83 | 2.81% | 4.86% |
MID-CAP | ||||||||
RGEN | 9.4B | 134.2M | 4.73% | -21.54% | 68.08 | 70.03 | -82.77% | -13.43% |
SMALL-CAP | ||||||||
PACB | 2.4B | 146.1M | -8.89% | 61.75% | -7.4 | 16.16 | 4.72% | -55.19% |
QTRX | 960.9M | 112.0M | 5.18% | 169.83% | -14.6 | 8.58 | 0.83% | 16.42% |
ADPT | 749.3M | 189.6M | -19.57% | -31.57% | -3.92 | 3.95 | 18.74% | 17.75% |
HBIO | 175.0M | 114.1M | -1.44% | 44.37% | -32.24 | 1.53 | -5.49% | -48.58% |
CDXS | 118.7M | 99.2M | -1.73% | -74.89% | -2.09 | 1.2 | -26.56% | -199.52% |
CDXC | 103.3M | 80.9M | -10.97% | -2.13% | -15.91 | 1.28 | 17.20% | 77.07% |
BNGO | 99.7M | 31.5M | -1.32% | 40.85% | -0.68 | 3.16 | 35.12% | -38.47% |
NSTG | 73.7M | 143.9M | -41.73% | -89.43% | -0.44 | 0.51 | 0.71% | -18.99% |
CSBR | 72.1M | 52.7M | -20.39% | -41.08% | -9.55 | 1.37 | 2.10% | -1984.29% |
-51.8%
98.7%
93.3%
90.1%
Y-axis is the maximum loss one would have experienced if Adaptive BioTech was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Revenue | 2.9% | 189,601,000 | 184,335,000 | 185,308,000 | 168,040,000 | 159,677,000 | 154,522,000 | 154,344,000 | 146,599,000 | 133,431,000 | 115,914,000 | 98,382,000 | 92,406,000 | 92,165,000 | 93,315,000 | 85,071,000 | 78,054,000 | 69,184,000 | 58,614,000 | 55,663,000 | 57,512,000 | 46,272,000 |
S&GA Expenses | -0.4% | 91,409,000 | 91,818,000 | 95,603,000 | 98,583,000 | 102,019,000 | 100,954,000 | 95,465,000 | 87,314,000 | 76,839,000 | 67,955,000 | 61,358,000 | 55,453,000 | 50,078,000 | 44,643,000 | 38,453,000 | 33,884,000 | 30,824,000 | 27,256,000 | 24,486,000 | 22,736,000 | 21,316,000 |
R&D Expenses | -3.5% | 131,718,000 | 136,518,000 | 141,756,000 | 145,233,000 | 145,647,000 | 146,410,000 | 142,343,000 | 143,475,000 | 137,717,000 | 125,909,000 | 116,072,000 | 101,430,000 | 91,622,000 | 82,157,000 | 70,705,000 | 60,583,000 | 49,860,000 | 42,785,000 | 39,157,000 | 38,470,000 | 37,808,000 |
EBITDA | - | - | - | - | - | -190,369,000 | -192,659,000 | -195,044,000 | - | - | -123,907,000 | -123,907,000 | -46,286,000 | -46,286,000 | -46,286,000 | -46,286,000 | - | - | - | - | - | - |
EBITDA Margin | - | - | - | - | - | -1.19 | -1.25 | -1.26 | - | - | -1.07 | -1.26 | -0.50 | -0.50 | -0.50 | -0.54 | - | - | - | - | - | - |
Interest Expenses | 9.8% | 11,374,000 | 10,358,667 | 4,238,000 | 2,612,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBT Margin | - | - | - | - | - | -1.30 | -1.34 | -1.34 | - | - | -1.26 | -1.49 | -0.74 | -0.74 | -0.74 | -0.81 | - | - | - | - | - | - |
Net Income | 2.2% | -190,918,000 | -195,154,000 | -200,191,000 | -221,496,000 | -232,118,000 | -236,070,000 | -207,279,000 | -197,113,000 | -177,929,000 | -155,466,000 | -146,227,000 | -122,268,000 | -99,499,000 | -81,623,000 | -68,606,000 | -61,266,000 | -55,608,000 | -52,442,000 | -46,447,000 | -41,570,000 | -49,972,000 |
Net Income Margin | 100.0% | - | -1.06 | -1.08 | -1.32 | -1.45 | -1.48 | -1.34 | -1.30 | -1.28 | -1.34 | -1.49 | -1.32 | -1.08 | -0.87 | -0.81 | - | - | - | - | - | - |
Free Cashflow | 100.0% | - | -194,840,000 | -200,294,000 | -230,804,000 | -241,026,000 | -247,917,000 | -254,473,000 | -240,616,000 | -233,917,000 | -208,003,000 | -168,486,000 | -148,479,000 | -130,684,000 | -114,837,000 | 194,204,000 | - | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2018Q4 | 2017Q4 |
Assets | -3.4% | 765 | 791 | 857 | 884 | 807 | 858 | 923 | 993 | 1,033 | 1,072 | 1,116 | 1,095 | 855 | 875 | 912 | 917 | 601 | 333 | 362 |
Current Assets | -4.9% | 477 | 501 | 562 | 564 | 439 | 419 | 403 | 467 | 644 | 765 | 727 | 877 | 600 | 585 | 613 | 601 | 442 | 181 | 205 |
Cash Equivalents | 15.5% | 109 | 95.00 | 90.00 | 218 | 76.00 | 115 | 139 | 122 | 184 | 174 | 123 | 497 | 365 | 213 | 97.00 | 75.00 | 48.00 | 55.00 | 85.00 |
Inventory | -4.6% | 19.00 | 20.00 | 14.00 | 17.00 | 19.00 | 21.00 | 19.00 | 18.00 | 19.00 | 17.00 | 14.00 | 11.00 | 11.00 | 11.00 | 9.00 | 9.00 | 8.00 | 8.00 | 5.00 |
Net PPE | -2.3% | 79.00 | 81.00 | 83.00 | 87.00 | 87.00 | 86.00 | 85.00 | 88.00 | 75.00 | 56.00 | 40.00 | 31.00 | 27.00 | 25.00 | 60.00 | 47.00 | 22.00 | 19.00 | 14.00 |
Goodwill | 0% | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 | 119 |
Liabilities | 0.3% | 369 | 368 | 393 | 396 | 288 | 305 | 319 | 341 | 340 | 346 | 373 | 320 | 325 | 323 | 341 | 331 | 324 | 30.00 | 26.00 |
Current Liabilities | 5.8% | 95.00 | 90.00 | 110 | 104 | 111 | 115 | 114 | 122 | 117 | 107 | 105 | 101 | 93.00 | 78.00 | 78.00 | 73.00 | 75.00 | 23.00 | 21.00 |
Shareholder's Equity | -6.6% | 396 | 424 | 464 | 488 | 518 | 553 | 604 | 652 | 693 | 726 | 743 | 775 | 530 | 552 | 571 | 586 | - | - | - |
Retained Earnings | -4.9% | -1,024 | -976 | -919 | -878 | -833 | -781 | -718 | -657 | -601 | -552 | -511 | -467 | -430 | -396 | -365 | -344 | -330 | -295 | -249 |
Additional Paid-In Capital | 1.3% | 1,422 | 1,403 | 1,387 | 1,373 | 1,358 | 1,340 | 1,324 | 1,309 | 1,295 | 1,277 | 1,254 | 1,241 | 958 | 945 | 936 | 930 | 46.00 | 38.00 | 25.00 |
Shares Outstanding | 0.3% | 145 | 144 | 143 | 143 | 142 | 142 | 141 | 141 | 140 | 139 | 138 | 129 | 127 | 126 | 69.00 | 51.00 | 13.00 | 13.00 | 12.00 |
Minority Interest | -1.5% | -0.07 | -0.07 | -0.07 | -0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - |
Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Cashflow From Operations | 13.2% | -155,135 | -178,644 | -183,945 | -207,752 | -208,787 | -198,935 | -192,727 | -178,745 | -182,458 | -176,322 | -149,683 | -136,630 | -119,612 | -104,505 | 205,404 | 226,785 | 245,237 | 348,276 | -32,259 | -46,744 | -30,326 |
Share Based Compensation | 5.5% | 60,452 | 57,287 | 55,477 | 53,058 | 50,559 | 47,628 | 43,251 | 38,619 | 33,446 | 28,570 | 24,761 | 20,929 | 17,759 | 14,718 | 13,124 | 12,724 | 11,977 | 11,045 | 11,149 | 9,906 | 9,600 |
Cashflow From Investing | 115.5% | 60,773 | 28,196 | 2,905 | 167,661 | 88,378 | 125,079 | 181,210 | -226,051 | -302,029 | -165,984 | -117,044 | 269,685 | 106,079 | -116,762 | -481,697 | -500,748 | -234,763 | -252,552 | 736 | 20,532 | -64,052 |
Cashflow From Financing | -1.9% | 127,667 | 130,188 | 132,265 | 135,537 | 12,943 | 15,281 | 27,146 | 30,121 | 303,233 | 303,242 | 293,587 | 289,080 | 332,592 | 324,751 | 319,916 | 318,448 | -1,045 | 612 | 1,248 | 228 | 1,826 |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Income Statement [Abstract] | ||||
Revenue | $ 48,926 | $ 43,660 | $ 86,573 | $ 82,280 |
Operating expenses | ||||
Cost of revenue | 17,910 | 13,221 | 36,591 | 26,413 |
Research and development | 32,237 | 37,037 | 64,838 | 74,876 |
Sales and marketing | 23,872 | 24,281 | 46,180 | 50,374 |
General and administrative | 22,302 | 21,200 | 43,133 | 45,344 |
Amortization of intangible assets | 423 | 423 | 842 | 842 |
Total operating expenses | 96,744 | 96,162 | 191,584 | 197,849 |
Loss from operations | (47,818) | (52,502) | (105,011) | (115,569) |
Interest and other income, net | 3,612 | 418 | 6,636 | 689 |
Interest expense | (3,605) | (7,136) | ||
Net loss | (47,811) | (52,084) | (105,511) | (114,880) |
Add: Net loss attributable to noncontrolling interest | 1 | 38 | 2 | 98 |
Net loss attributable to Adaptive Biotechnologies Corporation | $ (47,810) | $ (52,046) | $ (105,509) | $ (114,782) |
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic | $ (0.33) | $ (0.37) | $ (0.73) | $ (0.81) |
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic | 144,397,693 | 142,363,589 | 143,956,867 | 142,032,261 |
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted | $ (0.33) | $ (0.37) | $ (0.73) | $ (0.81) |
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted | 144,397,693 | 142,363,589 | 143,956,867 | 142,032,261 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 109,240 | $ 90,030 |
Short-term marketable securities (amortized cost of $308,885 and $412,282, respectively) | 307,990 | 408,166 |
Accounts receivable, net | 31,545 | 40,057 |
Inventory | 18,960 | 14,453 |
Prepaid expenses and other current assets | 9,074 | 9,440 |
Total current assets | 476,809 | 562,146 |
Long-term assets | ||
Property and equipment, net | 79,390 | 83,447 |
Operating lease right-of-use assets | 77,109 | 80,763 |
Restricted cash | 2,923 | 2,398 |
Intangible assets, net | 5,985 | 6,827 |
Goodwill | 118,972 | 118,972 |
Other assets | 3,352 | 2,064 |
Total assets | 764,540 | 856,617 |
Current liabilities | ||
Accounts payable | 9,163 | 8,084 |
Accrued liabilities | 8,356 | 12,424 |
Accrued compensation and benefits | 10,554 | 15,935 |
Current portion of operating lease liabilities | 9,345 | 9,230 |
Current portion of deferred revenue | 57,917 | 64,115 |
Total current liabilities | 95,335 | 109,788 |
Long-term liabilities | ||
Operating lease liabilities, less current portion | 94,176 | 98,772 |
Deferred revenue, less current portion | 50,895 | 58,599 |
Revenue interest liability, net | 128,167 | 125,360 |
Total liabilities | 368,573 | 392,519 |
Commitments and contingencies (Note 9) | ||
Shareholders’ equity | ||
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued and outstanding at June 30, 2023 and December 31, 2022 | ||
Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2023 and December 31, 2022; 144,645,118 and 143,105,002 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 14 | 14 |
Additional paid-in capital | 1,421,506 | 1,387,349 |
Accumulated other comprehensive loss | (893) | (4,116) |
Accumulated deficit | (1,024,591) | (919,082) |
Total Adaptive Biotechnologies Corporation shareholders’ equity | 396,036 | 464,165 |
Noncontrolling interest | (69) | (67) |
Total shareholders’ equity | 395,967 | 464,098 |
Total liabilities and shareholders’ equity | $ 764,540 | $ 856,617 |